NDAINTRAVENOUSPOWDER
Approved
Jul 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
8/8 — Comprehensive
KYPROLIS (carfilzomib) by Dr. Reddy's Laboratories is proteasome inhibitors [moa]. Approved for multiple myeloma, relapsed or refractory multiple myeloma. First approved in 2012.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYPROLIS (carfilzomib) is an intravenous proteasome inhibitor approved in 2012 for treatment of refractory multiple myeloma, often used in combination with dexamethasone. The drug works by inhibiting the 20S proteasome, leading to accumulation of pro-apoptotic proteins and cancer cell death. KYPROLIS represents an important second-generation proteasome inhibitor option in the multiple myeloma treatment armamentarium, following bortezomib as a comparator therapy.
$0.0BPart D
7.3 years to LOEMechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Worked on KYPROLIS at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.